Quantitative metabolic profiling of lipid mediators

Molecular Nutrition and Food Research

Volumn 57, Issue 8, 2013, Pages 1359-1377

  Balgoma, David ^a   Checa, Antonio ^a   Sar, Daniel García ^a   Snowden, Stuart ^a   Wheelock, Craig E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Disease; Inflammation; Lipidomics; Lipids; MS

Indexed keywords

ENDOCANNABINOID; ETHANOLAMINE DERIVATIVE; LIPID; N ACYLETHANOLAMINES; N-ACYLETHANOLAMINES; OXYLIPIN; SPHINGOLIPID;

ARTICLE; DISEASES; HEALTH; HUMAN; INFLAMMATION; LIPID METABOLISM; LIPIDOMICS; METABOLISM; METABOLOME; MULTIPLE SCLEROSIS; PHYSIOLOGY;

DISEASE; INFLAMMATION; LIPIDOMICS; LIPIDS; MS;

ENDOCANNABINOIDS; ETHANOLAMINES; HEALTH; HUMANS; LIPID METABOLISM; METABOLOME; OXYLIPINS; SPHINGOLIPIDS;

EID: 84881275618     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200840     Document Type: Article

References (241)

1. Shimizu, T., Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 123-150.
2. Charo, I. F., Ransohoff, R. M., The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 2006, 354, 610-621.
3. Lemanske, R. F., Busse, W. W., Asthma: clinical expression and molecular mechanisms. J. Allergy Clin. Immunol. 2010, 125, S95-S102.
4. Chung, K. F., Adcock, I. M., Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur. Resp. J. 2008, 31, 1334-1356.
5. Gregor, M. F., Hotamisligil, G. S., Inflammatory Mechanisms in Obesity. Annu. Rev. Immunol, 2011, 29, 415-445.
6. Mantovani, A., Allavena, P., Sica, A., Balkwill, F., Cancer-related inflammation. Nature 2008, 454, 436-444.
7. Holmes, C., Cunningham, C., Zotova, E., Woolford, J. et al., Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009, 73, 768-774.
8. Yetukuri, L., Ekroos, K., Vidal-Puig, A., Oresic, M., Informatics and computational strategies for the study of lipids. Mol. Biosyst. 2008, 4, 121-127.
9. Funk, C. D., Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294, 1871-1875.
10. Heller, A., Koch, T., Schmeck, J., van Ackern, K., Lipid mediators in inflammatory disorders. Drugs 1998, 55, 487-496.
11. Lundström, S. L., Yang, J., Källberg, H. J., Thunberg, S. et al., Allergic asthmatics show divergent lipid mediator profiles from healthy controls both at baseline and following birch pollen provocation. Plos One 2012, 7, e33780.
12. Ricciotti, E., FitzGerald, G. A., Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 986-1000.
13. Wymann, M. P., Schneiter, R., Lipid signalling in disease. Nat. Rev. Mol. Cell Biol. 2008, 9, 162-176.
14. Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B. et al., Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 2010, 51, 3299-3305.
15. Wenk, M. R., The emerging field of lipidomics. Nat. Rev. Drug. Discov. 2005, 4, 594-610.
16. Yang, J., Schmelzer, K., Georgi, K., Hammock, B. D., Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal. Chem. 2009, 81, 8085-8093.
17. Murphy, R. C., Axelsen, P. H., Mass spectrometric analysis of long-chain lipids. Mass Spectrom. Rev. 2011, 30, 579-599.
18. Pulfer, M., Murphy, R. C., Electrospray mass spectrometry of phospholipids. Mass Spectrom. Rev. 2003, 22, 332-364.
19. Bligh, E. G., Dyer, W. J., A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37, 911-917.
20. Folch, J., Lees, M., Stanley, G. H. S., A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226, 497-509.
21. Matyash, V., Liebisch, G., Kurzchalia, T. V., Shevchenko, A. et al., Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J. Lipid Res. 2008, 49, 1137-1146.
22. Kim, H. Y., Salem, N., Separation of lipid classes by solid phase extraction. J. Lipid Res. 1990, 31, 2285-2289.
23. Newman, J. W., Watanabe, T., Hammock, B. D., The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J. Lipid Res. 2002, 43, 1563-1578.
24. Lundström, S. L., Saluja, R., Adner, M., Haeggström, J. Z. et al., Lipid mediator metabolic profiling demonstrates differences in eicosanoid patterns in two phenotypically distinct mast cell populations. J. Lipid Res. 2013, 54, 116-126.
25. Murphy, R. C., Barkley, R. M., Berry, K. Z., Hankin, J. et al., Electrospray ionization and tandem mass spectrometry of eicosanoids. Anal. Biochem. 2005, 346, 1-42.
26. 2-regulated phospholipid fatty acid incorporation and remodeling. Biochimie 2010, 92, 645-650.
27. Matuszewski, B. K., Constanzer, M. L., Chavez-Eng, C. M., Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75, 3019-3030.
28. Postle, A. D., Wilton, D. C., Hunt, A. N., Attard, G. S., Probing phospholipid dynamics by electrospray ionisation mass spectrometry. Prog. Lipid Res. 2007, 46, 200-224.
29. Balgoma, D., Larsson, J., Rokach, J., Lawson, J. A. et al., Quantification of lipid mediator metabolites in human urine from asthma patients by electrospray ionization mass spectrometry: controlling matrix effects. Submitted.
30. Koivusalo, M., Haimi, P., Heikinheimo, L., Kostiainen, R. et al., Quantitative determination of phospholipid compositions by ESI-MS: effects of acyl chain length, unsaturation, and lipid concentration on instrument response. J. Lipid Res. 2001, 42, 663-672.
31. Simons, K., Ikonen, E., Functional rafts in cellmembranes. Nature 1997, 387, 569-572.
32. Bartke, N., Hannun, Y. A., Bioactive sphingolipids: metabolism and function. J. Lipid. Res. 2009, 50(Suppl.), S91-S96.
33. Michel, C., van Echten-Deckert, G., Conversion of dihydroceramide to ceramide occurs at the cytosolic face of the endoplasmic reticulum. FEBS Lett. 1997, 416, 153-155.
34. Merrill, A. H., Jr., Wang, M. D., Park, M., Sullards, M. C., (Glyco)sphingolipidology: an amazing challenge and opportunity for systems biology. Trends Biochem. Sci. 2007, 32, 457-468.
35. Merrill, A. H., Sullards, M. C., Liu, Y., Chen, Y., Analysis of mammalian sphingolipids by liquid chromatography tandem mass spectrometry (LC-MS/MS) and tissue imaging mass spectrometry (TIMS). Biochim. Biophys. Acta 2011, 1811, 838-853.
36. Merrill, A. H., Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem. Rev. 2011, 111, 6387-6422.
37. Pettus, B. J., Chalfant, C. E., Hannun, Y. A., Sphingolipids in Inflammation: roles and implications. Curr. Mol. Med. 2004, 4, 405-418.
38. Hla, T., Dannenberg, A. J., Sphingolipid signaling in metabolic disorders. Cell Metab. 2012, 16, 420-434.
39. Nixon, G. F., Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br. J. Pharmacol. 2009, 158, 982-993.
40. Fyrst, H., Saba, J. D., An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat. Chem. Biol. 2010, 6, 489-497.
41. Mitra, P., Oskeritzian, C. A., Payne, S. G., Beaven, M. A. et al., Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc. Natl. Acad. Sci. USA 2006, 103, 16394-16399.
42. Jolly, P. S., Bektas, M., Olivera, A., Gonzalez-Espinosa, C. et al., Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. J. Exp. Med. 2004, 199, 959-970.
43. Pettus, B. J., Bielawski, J., Porcelli, A. M., Reames, D. L. et al., The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-α. FASEB J. 2003, 17, 1411-1421.
44. Cowart, L. A., Sphingolipids: players in the pathology of metabolic disease. Trends Endocrinol. Metab. 2009, 20, 34-42.
45. Egom, E. E., Mamas, M. A., Clark, A. L., The potential role of sphingolipid- mediated cell signaling in the interaction between hyperglycemia, acute myocardial infarction and heart failure. Expert. Opin. Ther. Targets 2012, 16, 791-800.
46. van Echten-Deckert, G., Walter, J., Sphingolipids: critical players in Alzheimer's disease. Prog. Lipid Res. 2012, 51, 378-393.
47. Podbielska, M., Krotkiewski, H., Hogan, E. L., Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis. Neurochem. Res. 2012, 37, 1154-1169.
48. Jana, A., Pahan, K., Sphingolipids in multiple sclerosis. Neuromolecular Med. 2010, 12, 351-361.
49. Haughey, N. J., Sphingolipids in neurodegeneration. Neuromolecular Med. 2010, 12, 301-305.
50. Skoura, A., Sanchez, T., Claffey, K., Mandala, S. M. et al., Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J. Clin. Invest. 2007, 117, 2506-2516.
51. Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E. et al., S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF. Proc. Natl. Acad. Sci. USA 2005, 102, 9270-9275.
52. Miron, V. E., Schubart, A., Antel, J. P., Central nervous system-directed effects of FTY720 (fingolimod). J. Neurol. Sci. 2008, 274, 13-17.
53. Cyster, J. G., Schwab, S. R., in: Paul, W. E. (Ed.), Annual Review of Immunology, Vol 30, Annual Reviews, Palo Alto 2012, pp. 69-94.
54. Guangwei, L., Kai, Y., Samir, B., Sharad, S. et al., The S1P1-mTOR axis directs the reciprocal differentiation of TH1 and Treg cells. Nat. Immunol. 2010, 11, 1047-1056.
55. Pelletier, D., Hafler, D. A., Fingolimod for multiple sclerosis. N. Engl. J. Med. 2012, 366, 339-347.
56. Chun, J., Hartung, H. P., Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 2010, 33, 91-101.
57. Mehling, M., Lindberg, R., Raulf, F., Kuhle, J. et al., Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010, 75, 403-410.
58. Kim, S., Steelman, A. J., Zhang, Y., Kinney, H. C. et al., Aberrant upregulation of astroglial ceramide potentiates oligodendrocyte injury. Brain Pathol. 2012, 22, 41-57.
59. Qin, J., Berdyshev, E., Goya, J., Natarajan, V. et al., Neurons and oligodendrocytes recycle sphingosine 1-phosphate to ceramide: significance for apoptosis and multiple sclerosis. J. Biol. Chem. 2010, 285, 14134-14143.
60. Lahiri, S., Futerman, A., The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol. Life Sci. 2007, 64, 2270-2284.
61. O'Keeffe, J., Gately, C. M., Counihan, T., Hennessy, M. et al., T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to alpha-galactosylceramide are impaired. J. Neurol. Sci. 2008, 275, 22-28.
62. Ilan, Y., Elstein, D., Zimran, A., Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent. Immunol. Cell Biol. 2009, 87, 514-524.
63. Saadat, L., Dupree, J. L., Kilkus, J., Han, X. et al., Absence of oligodendroglial glucosylceramide synthesis does not result in CNS myelin abnormalities or alter the dysmyelinating phenotype of CGT-deficient mice. Glia 2010, 58, 391-398.
64. Mielke, M. M., Haughey, N. J., Bandaru, V. V., Weinberg, D. D. et al., Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J. Alzheimers Dis. 2011, 27, 259-269.
65. Mielke, M. M., Haughey, N. J., Ratnam Bandaru, V. V., Schech, S. et al., Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement. 2010, 6, 378-385.
66. Mielke, M. M., Bandaru, V. V., McArthur, J. C., Chu, M. et al., Disturbance in cerebral spinal fluid sphingolipid content is associated with memory impairment in subjects infected with the human immunodeficiency virus. J. Neurovirol. 2010, 16, 445-456.
67. Mielke, M. M., Bandaru, V. V., Haughey, N. J., Rabins, P. V. et al., Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol. Aging 2010, 31, 17-24.
68. Schiffmann, S., Sandner, J., Schmidt, R., Birod, K. et al., The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis. J. Lipid Res. 2009, 50, 32-40.
69. Hicks, A. A., Pramstaller, P. P., Johansson, A., Vitart, V. et al., Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet. 2009, 5, e1000672.
70. Han, X. L., Gross, R. W., Shotgun lipidomics: multidimensional MS analysis of cellular lipidomes. Expert. Rev. Proteomics. 2005, 2, 253-264.
71. Han, X. L., Gross, R. W., Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 2005, 24, 367-412.
72. Merrill, A. H., Shaner, R. L., Allegood, J. C., Park, H. et al., Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers. J. Lipid Res. 2009, 50, 1692-1707.
73. Merrill, A. H., Sullards, M. C., Allegood, J. C., Kelly, S. et al., Structure-specific, quantitative methods for analysis of sphingolipids by liquid chromatography-tandem mass spectrometry: "inside-out" sphingolipidomics. Methods Enzymol. 2007, 432, 83-115.
74. Merrill, A. H., Sullards, M. C., Allegood, J. C., Kelly, S. et al., Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 2005, 36, 207-224.
75. Farwanah, H., Pierstorff, B., Schmelzer, C. E. H., Raith, K. et al., Separation and mass spectrometric characterization of covalently bound skin ceramides using LC/APCI-MS and Nano-ESI-MS/MS. J. Chromatogr. B 2007, 852, 562-570.
76. Farwanah, H., Kolter, T., Sandhoff, K., Mass spectrometric analysis of neutral sphingolipids: methods, applications, and limitations. Biochim. Biophys. Acta 2011, 1811, 854-860.
77. Farwanah, H., Wirtz, J., Kolter, T., Raith, K. et al., Normal phase liquid chromatography coupled to quadrupole time of flight atmospheric pressure chemical ionization mass spectrometry for separation, detection and mass spectrometric profiling of neutral sphingolipids and cholesterol. J. Chromatogr. B 2009, 877, 2976-2982.
78. Lands, W. E. M., Stories about acyl chains. Biochim. Biophys. Acta 2000, 1483, 1-14.
79. 2 superfamily and its group numbering system. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2006, 1761, 1246-1259.
80. 2 and lysophospholipid acyltransferases. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2009, 1791, 1103-1113.
81. 2 in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling. Biochem. J. 2002, 364, 695-702.
82. Chilton, F. H., Fonteh, A. N., Surette, M. E., Triggiani, M. et al., Control of arachidonate levels within inflammatory cells. Biochim. Biophys. Acta Lipid. Lipid. Met. 1996, 1299, 1-15.
83. Balgoma, D., Astudillo, A. M., Pérez-Chacón, G., Montero, O. et al., Markers of monocyte activation revealed by lipidomic profiling of arachidonic acid-containing phospholipids. J. Immunol. 2010, 184, 3857-3865.
84. McIntyre, T. M., Prescott, S. M., Stafforini, D. M., The emerging roles of PAF acetylhydrolase. J. Lipid Res. 2009, 50, S255-S259.
85. Di Paolo, G., De Camilli, P., Phosphoinositides in cell regulation and membrane dynamics. Nature 2006, 443, 651-657.
86. Gómez-Fernández, J. C., Corbalán-García, S., Diacylglycerols, multivalent membrane modulators. Chem. Phys. Lipids 2007, 148, 1-25.
87. 2+ release channels. Physiol. Rev. 2007, 87, 593-658.
88. Zwaal, R. F. A., Schroit, A. J., Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997, 89, 1121-1132.
89. Kay, J. G., Koivusalo, M., Ma, X. X., Wohland, T. et al., Phosphatidylserine dynamics in cellular membranes. Mol. Biol. Cell 2012, 23, 2198-2212.
90. Yeung, T., Gilbert, G. E., Shi, J., Silvius, J. et al., Membrane phosphatidylserine regulates surface charge and protein localization. Science 2008, 319, 210-213.
91. Leventis, P. A., Grinstein, S., The distribution and function of phosphatidylserine in cellular membranes. Annu. Rev. Biophys 2010, 39, 407-427.
92. Veldhuizen, R., Nag, K., Orgeig, S., Possmayer, F., The role of lipids in pulmonary surfactant. Biochim. Biophys. Acta-Mol. Basis Dis. 1998, 1408, 90-108.
93. Stafforini, D. M., McIntyre, T. M., Zimmerman, G. A., Prescott, S. M., Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit. Rev. Clin. Lab. Sci. 2003, 40, 643-672.
94. Prescott, S. M., Zimmerman, G. A., Stafforini, D. M., McIntyre, T. M., Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 2000, 69, 419-445.
95. Gräler, M. H., Goetzl, E. J., Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. Biochim. Biophys. Acta 2002, 1582, 168-174.
96. Ishii, I., Fukushima, N., Ye, X. Q., Chun, J., Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 2004, 73, 321-354.
97. McIntyre, T. M., Pontsler, A. V., Silva, A. R., St Hilaire, A. et al., Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARg agonist. Proc. Natl. Acad. Sci. USA 2003, 100, 131-136.
98. Chicco, A. J., Sparagna, G. C., Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am. J. Physiol. Cell Physiol. 2007, 292, C33-C44.
99. Zwaal, R. F. A., Comfurius, P., Bevers, E. M., Surface exposure of phosphatidylserine in pathological cells. Cell. Mol. Life Sci. 2005, 62, 971-988.
100. Wright, S. M., Hockey, P. M., Enhorning, G., Strong, P. et al., Altered airway surfactant phospholipid composition and reduced lung function in asthma. J. Appl. Physiol. 2000, 89, 1283-1292.
101. Yuan, T. L., Cantley, L. C., PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27, 5497-5510.
102. Mills, G. B., Moolenaar, W. H., The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 2003, 3, 582-591.
103. Ejsing, C. S., Duchoslav, E., Sampaio, J., Simons, K. et al., Automated identification and quantification of glycerophospholipid molecular species by multiple precursor ion scanning. Anal. Chem. 2006, 78, 6202-6214.
104. Ejsing, C. S., Sampaio, J. L., Surendranath, V., Duchoslav, E. et al., Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry. Proc. Natl. Acad. Sci. USA 2009, 106, 2136-2141.
105. Milton, A. S., Wendlandt, S., Effects on body temperature of prostaglandins of the A, E and F series on injection into the third ventricle of unanaesthetized cats and rabbits. J. Physiol. 1971, 218, 325-336.
106. 1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 2010, 16, 592-597.
107. Serhan, C. N., Chiang, N., Van Dyke, T. E., Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008, 8, 349-361.
108. 4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 2008, 9, 873-879.
109. Lundström, S., Balgoma, D., Wheelock, Å. M., Haeggström, J. Z. et al., Lipid mediator profiling in pulmonary disease. Curr. Pharm. Biotechnol. 2011, 12, 1026-1052.
110. Moghaddam, M. F., Motoba, K., Borhan, B., Pinot, F. et al., Novel metabolic pathways for linoleic and arachidonic acid metabolism. Biochim. Biophys. Acta 1996, 1290, 327-339.
111. Gundlach, H., Zenk, M. H., Biological activity and biosynthesis of pentacyclic oxylipins: the linoleic acid pathway. Phytochemistry 1998, 47, 527-537.
112. Serhan, C. N., Gotlinger, K., Hong, S., Arita, M., Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostagl. Other Lipid Mediat. 2004, 73, 155-172.
113. Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A. et al., Cyclooxygenase in biology and disease. FASEB J. 1998, 12, 1063-1073.
114. Feussner, I., Wasternack, C., The lipoxygenase pathway. Annu. Rev. Plant Biol. 2002, 53, 275-297.
115. Guengerich, F., in: Ortiz de Montellano, P. R. (Ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry, Springer, New York, NY 2005, pp. 377-530.
116. Herschman, H. R., Hall, W., Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev. 1994, 13, 241-256.
117. Chenevard, R., Hürlimann, D., Béchir, M., Enseleit, F. et al., Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003, 107, 405-409.
118. Schrör, K., Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin. Thromb. Hemost. 1997, 23, 349-356.
119. Ivanov, I., Heydeck, D., Hofheinz, K., Roffeis, J. et al., Molecular enzymology of lipoxygenases. Arch. Biochem. Biophys. 2010, 503, 161-174.
120. Haeggström, J. Z., Funk, C. D., Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem. Rev. 2011, 111, 5866-5898.
121. Rai, G., Kenyon, V., Jadhav, A., Schultz, L. et al., Discovery of potent and selective inhibitors of human reticulocyte 15-lipoxygenase-1. J. Med. Chem. 2010, 53, 7392-7404.
122. Lewis, R. A., Austen, K. F., Soberman, R. J., Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 1990, 323, 645-655.
123. 4 hydrolase, a bifunctional enzyme in inflammation. Nat. Struct. Bio. 2001, 8, 131-135.
124. Sala, A., Folco, G., Neutrophils, endothelial cells, and cysteinyl leukotrienes: a new approach to neutrophil-dependent inflammation? Biochem. Biophys. Res. Commun. 2001, 283, 1003-1006.
125. 4 synthase. Nature 2007, 448, 613-616.
126. Zeldin, D. C., Wei, S. Z., Falck, J. R., Hammock, B. D. et al., Metabolism of epoxyeicosatrienoic acids by cytosolic epoxide hydrolase: substrate structural determinants of asymmetric catalysis. Arch. Biochem. Biophys. 1995, 316, 443-451.
127. Spector, A. A., Fang, X., Snyder, G. D., Weintraub, N. L., Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. 2004, 43, 55-90.
128. Newman, J. W., Morisseau, C., Hammock, B. D., Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog. Lipid Res. 2005, 44, 1-51.
129. Li, N., Liu, J.-Y., Qiu, H., Harris, T. R. et al., Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease. Congest. Heart Fail. 2011, 17, 42-46.
130. Lundström, S. L., Levänen, B., Nording, M., Klepczynska-Nyström, A. et al., Asthmatics exhibit altered oxylipin profiles compared to healthy individuals after subway air exposure. PLoS One 2011, 6, e23864.
131. Dong, H., Metabolomic profiling of lipids for biomarker discovery. Biochem. Anal. Biochem. 2012, 01, e115.
132. Podolin, P. L., Bolognese, B. J., Foley, J. F., Long, E. et al., In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 2013, Doi:10.1016/j.prostaglandins.2013.02.001
133. Hamman, M. A., Thompson, G. A., Hall, S. D., Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem. Pharmacol. 1997, 54, 33-41.
134. Boeglin, W. E., Kim, R. B., Brash, A. R., A 12R-lipoxygenase in human skin: mechanistic evidence, molecular cloning, and expression. Proc. Natl. Acad. Sci. USA 1998, 95, 6744-6749.
135. Camacho, M., Godessart, N., Antón, R., Garca, M. et al. Interleukin-1 enhances the ability of cultured human umbilical vein endothelial cells to oxidize linoleic acid. J. Biol. Chem. 1995, 270, 17279-17286.
136. Baer, A. N., Costello, P. B., Green, F. A., Stereospecificity of the hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids produced by cultured bovine endothelial cells. Biochim. Biophys. Acta 1991, 1085, 45-52.
137. Bittleman, D. B., Casale, T. B., 5-Hydroxyeicosatetraenoic acid (HETE)-induced neutrophil transcellular migration is dependent upon enantiomeric structure. Am. J. Respir. Cell Mol. Biol. 1995, 12, 260-267.
138. 2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J. Biol. Chem. 2002, 277, 50828-50833.
139. Sales, K. J., Katz, A. A., Howard, B., Soeters, R. P. et al., Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res. 2002, 62, 424-432.
140. Senior, J., Sangha, R., Baxter, G. S., Marshall, K. et al., In vitro characterization of prostanoid FP-, DP-, IP- and TP-receptors on the non-pregnant human myometrium. Br. J. Pharmacol. 1992, 107, 215-221.
141. Dorsam, R. T., Gutkind, J. S., G-protein-coupled receptors and cancer. Nat. Rev. Cancer 2007, 7, 79-94.
142. Hata, A. N., Breyer, R. M., Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 2004, 103, 147-166.
143. 2 receptor. Nature 1991, 349, 617-620.
144. Capra, V., Habib, A., Accomazzo, M. R., Ravasi, S. et al., Thromboxane prostanoid receptor in human airway smooth muscle cells: a relevant role in proliferation. Eur. J. Pharmacol. 2003, 474, 149-159.
145. 2 in normal and asthmatic men. N. Engl. J. Med. 1984, 311, 209-213.
146. 2 from human skin in vivo and in vitro during immediate allergic reactions. Br. J. Pharmacol. 1988, 94, 773-780.
147. Gardiner, P. J., Characterization of prostanoid relaxant/inhibitory receptors (ψ) using a highly selective agonist, TR4979. Br. J. Pharmacol. 1986, 87, 45-56.
148. 2-induced pain responses by use of EP1 and EP3 receptor knockout mice. Br. J. Pharmacol. 2001, 133, 438-444.
149. 2 on allergic airway responses in the rat. J. Immunol. 2002, 169, 3963-3969.
150. Doi, Y. M. T., Nishizawa, M., Mabuchi, T., Mori, H. et al., Central nociceptive role of prostacyclin (IP) receptor induced by peripheral inflammation. Neuroreport 2002, 13, 93-96.
151. Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M. et al., Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388, 678-682.
152. 2. J. Neurosci. 2001, 21, 1750-1756.
153. Abrams, P. H., Feneley, R. C. L., The actions of prostaglandins on the smooth muscle of the human urinary tract in vitro. Br. J. Urol. 1975, 47, 909-915.
154. Kuehl, F. A., Egan, R. W., Prostaglandins, arachidonic acid, and inflammation. Science 1980, 210, 978-984.
155. 2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310, 1504-1510.
156. 2a vaginal gel for ripening the cervix before induction of labour. Br. J. Obstet. Gynaecol. 1979, 86, 167-170.
157. 1 on pulmonary arterial hypertension following corrective surgery for congenital heart disease. J. Cardiovasc. Pharmacol. Ther. 2012, 17, 303-307.
158. 1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study. J. Heart Lung Transplant. 2006, 25, 1070-1076.
159. 1 and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int. J. Impot. Res. 2002, 14(Suppl 1), S38-S42.
160. Grosser, T., Yu, Y., FitzGerald, G. A., Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu. Rev. Med. 2010, 61, 17-33.
161. Fries, S., Grosser, T., Price, T. S., Lawson, J. A. et al., Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006, 130, 55-64.
162. 4 are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev. Res. 2009, 2, 322-329.
163. 2 in man. J. Biol. Chem. 1971, 246, 6713-6721.
164. Song, W. L., Lawson, J. A., Wang, M., Zou, H. et al., Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: A detailed HPLC/MS/MS method. Methods Enzymol. 2007, 433, 51-72.
165. Samuelsson, B., The discovery of the leukotrienes. Am. J. Respir. Crit. Care Med. 2000, 161, S2-S6.
166. Briscoe, C. P., Tadayyon, M., Andrews, J. L., Benson, W. G. et al., The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 2003, 278, 11303-11311.
167. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J. et al., Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA 1997, 94, 4318-4323.
168. Murphy, R. C., Gijón, M. A., Biosynthesis and metabolism of leukotrienes. Biochem. J. 2007, 405, 379-395.
169. Bisgaard, H., Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001, 56, 7-11.
170. Shastri, S., McNeill, J. R., Wilson, T. W., Poduri, R. et al., Cysteinyl leukotrienes mediate enhanced vasoconstriction to angiotensin II but not endothelin-1 in SHR. Am. J. Physiol. Heart Circ. Physiol. 2001, 281, H342-H349.
171. Parameswaran, K., Cox, G., Radford, K., Janssen, L. J. et al., Cysteinyl leukotrienes promote human airway smooth muscle migration. Am. J. Respir. Crit. Care Med. 2002, 166, 738-742.
172. 4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J. Exp. Med. 2009, 206, 2543-2555.
173. 4, and histamine in asthmatics. Am. Rev. Respir. Dis. 1992, 146, 96-103.
174. Boyce, J. A., Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol. Rev. 2007, 217, 168-185.
175. Turner, C. R., Breslow, R., Conklyn, M. J., Andresen, C. J. et al., In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma. J. Clin. Invest. 1996, 97, 381-387.
176. Sharon, P., Stenson, W. F., Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984, 86, 453-460.
177. Sánchez-Galán, E., Gómez-Hernández, A., Vidal, C., Martín-Ventura, J. L. et al., Leukotriene B4 enhances the activity of nuclear factor-κB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc. Res. 2009, 81, 216-225.
178. Janakiram, N. B., Mohammed, A., Rao, C. V., Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev. 2011, 30, 507-523.
179. Serhan, C. N., Hamberg, M., Samuelsson, B., Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. USA 1984, 81, 5335-5339.
180. Kohli, P., Levy, B. D., Resolvins and protectins: mediating solutions to inflammation. Br. J. Pharmacol. 2009, 158, 960-971.
181. Serhan, C. N., Petasis, N. A., Resolvins and protectins in inflammation resolution. Chem. Rev. 2011, 111, 5922-5943.
182. Serhan, C. N., Yang, R., Martinod, K., Kasuga, K. et al., Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 2009, 206, 15-23.
183. Serhan, C. N., Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am. J. Pathol. 2010, 177, 1576-1591.
184. Samuelsson, B., Dahlén, S. E., Lindgren, J. A., Rouzer, C. A. et al., Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987, 237, 1171-1176.
185. Chiang, N., Arita, M., Serhan, C. N., Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostagl. Leukot. Essent. Fatty Acids 2005, 73, 163-177.
186. 4 during the early phase of severe acute pancreatitis in rats. Scand. J. Gastroenterol. 2011, 46, 211-219.
187. 1 and ChemR23 to regulate Inflammation. J. Immunol. 2007, 178, 3912-3917.
188. Zhang, M. J., Spite, M., Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids. Annu. Rev. Nutr. 2012, 32, 203-227.
189. 4. Nat. Med. 2002, 8, 1018-1023.
190. 1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J. Immunol. 2007, 178, 496-502.
191. 1 receptor antagonism. FASEB J. 2007, 21, 3877-3884.
192. Neilson, A. P., Ren, J., Hong, Y. H., Sen, A. et al., Effect of fish oil on levels of R- and S-enantiomers of 5-, 12-, and 15-hydroxyeicosatetraenoic acids in mouse colonic mucosa. Nutr. Cancer 2011, 64, 163-172.
193. Liu, C., Xu, D., Liu, L., Schain, F. et al., 15-lipoxygenase-1 induces expression and release of chemokines in cultured human lung epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 297, L196-L203.
194. Chanez, P., Bonnans, C., Chavis, C., Vachier, I., 15-lipoxygenase: a Janus enzyme? Am. J. Respir. Cell Mol. Biol. 2002, 27, 655-658.
195. Morin, C., Sirois, M., Echave, V., Gomes, M. M. et al., Functional effects of 20-HETE on human bronchi: hyperpolarization and relaxation due to BKCa channel activation. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293, L1037-L1044.
196. Katoh, T., Takahashi, K., Capdevila, J., Karara, A. et al., Glomerular stereospecific synthesis and hemodynamic actions of 8, 9-epoxyeicosatrienoic acid in rat kidney. Am. J. Physiol. 1991, 261, F578-F586.
197. Harder, D. R., Campbell, W. B., Roman, R. J., Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J. Vasc. Res. 1995, 32, 79-92.
198. Roman, R. J., P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 2002, 82, 131-185.
199. Pokreisz, P., Fleming, I., Kiss, L., Barbosa-Sicard, E. et al., Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 2006, 47, 762-770.
200. Pascual, J. M. S., McKenzie, A., Yankaskas, J. R., Falck, J. R. et al., Epoxygenase metabolites of arachidonic acid affect electrophysiologic properties of rat tracheal epithelial cells1. J. Pharmacol. Exp. Ther. 1998, 286, 772-779.
201. Jacobs, E. R., Zeldin, D. C., The lung HETEs (and EETs) up. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H1-H10.
202. Hsi, L. C., Wilson, L., Nixon, J., Eling, T. E., 15-lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor gamma via the MAPK signaling pathway. J. Biol. Chem. 2001, 276, 34545-34552.
203. Gardner, H. W., Nelson, E. C., Tjarks, L. W., England, R. E., Acid-catalyzed transformation of 13(S)-hydroperoxylinoleic acid into epoxyhydroxyoctadecenoic and trihydroxyoctadecenoic acids. Chem. Phys. Lipids 1984, 35, 87-101.
204. Koeners, M. P., Wesseling, S., Ulu, A., Sepúlveda, R. L. et al., Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats. Am. J. Physiol. Endocrinol. Metab. 2011, 300, E691-E698.
205. Deems, R., Buczynski, M. W., Bowers Gentry, R., Harkewicz, R. et al., in: Brown, H. A. (Ed.), Methods in Enzymology, Academic Press, San Diego, CA 2007, pp. 59-82.
206. Shearer, G. C., Harris, W. S., Pedersen, T. L., Newman, J. W., Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J. Lipid Res. 2010, 51, 2074-2081.
207. Jahn, U., Galano, J. M., Durand, T., Beyond prostaglandins - Chemistry and biology of cyclic oxygenated metabolites formed by free-radical pathways from polyunsaturated fatty acids. Angew. Chem. Int. Ed. 2008, 47, 5894-5955.
208. Lee, S. H., Blair, I. A., Targeted chiral lipidomics analysis of bioactive eicosanoid lipids in cellular systems. BMB Rep. 2009, 42, 401-410.
209. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G. et al., Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
210. Hanus, L., Gopher, A., Almog, S., Mechoulam, R., Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 1993, 36, 3032-3034.
211. Zoerner, A. A., Gutzki, F. M., Batkai, S., May, M. et al., Quantification of endocannabinoids in biological systems by chromatography and mass spectrometry: a comprehensive review from an analytical and biological perspective. Biochim. Biophys. Acta 2011, 1811, 706-723.
212. De Petrocellis, L., Cascio, M. G., Di Marzo, V., The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol. 2004, 141, 765-774.
213. Hansen, H. S., Diep, T. A., N-acylethanolamines, anandamide and food intake. Biochem. Pharmacol. 2009, 78, 553-560.
214. Hansen, H. S., Moesgaard, B., Hansen, H. H., Petersen, G., N-acylethanolamines and precursor phospholipids - relation to cell injury. Chem. Phys. Lipids 2000, 108, 135-150.
215. McKinney, M. K., Cravatt, B. F., Annual Review of Biochemistry, Annual Reviews, Palo Alto 2005, pp. 411-432.
216. Ueda, N., Tsuboi, K., Uyama, T., N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog. Lipid Res. 2010, 49, 299-315.
217. Ueda, N., Tsuboi, K., Uyama, T., Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim. Biophys. Acta 2010, 1801, 1274-1285.
218. Mechoulam, R., Benshabat, S., Hanus, L., Ligumsky, M. et al., Identification of an endogenous 2-monoglyceride, present in the canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50, 83-90.
219. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S. et al., 2-Arachidonoylglycerol - A possible endogenous cannabinoid receptor-ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215, 89-97.
220. Bisogno, T., Ligresti, A., Di Marzo, V., The endocannabinoid signalling system: biochemical aspects. Pharmacol. Biochem. Behav. 2005, 81, 224-238.
221. Blankman, J. L., Simon, G. M., Cravatt, B. F., A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 2007, 14, 1347-1356.
222. Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A. et al., 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA 2001, 98, 3662-3665.
223. Porter, A. C., Sauer, J. M., Knierman, M. D., Becker, G. W. et al., Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 2002, 301, 1020-1024.
224. Bisogno, T., Melck, D., Bobrov, M. Y., Gretskaya, N. M. et al., N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 2000, 351, 817-824.
225. Oka, S., Tsuchie, A., Tokumura, A., Muramatsu, M. et al., Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J. Neurochem. 2003, 85, 1374-1381.
226. Buczynski, M. W., Parsons, L. H., Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. Br. J. Pharmacol. 2010, 160, 423-442.
227. Pacher, P., Batkai, S., Kunos, G., The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58, 389-462.
228. Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T. et al., Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor - Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 2000, 275, 605-612.
229. Starowicz, K., Nigam, S., Di Marzo, V., Biochemistry and pharmacology of endovanilloids. Pharmacol. Ther. 2007, 114, 13-33.
230. Balvers, M. G. J., Verhoeckx, K. C. M., Meijerink, J., Bijlsma, S. et al., Time-dependent effect of in vivo inflammation on eicosanoid and endocannabinoid levels in plasma, liver, ileum and adipose tissue in C57BL/6 mice fed a fish-oil diet. Int. Immunopharmacol. 2012, 13, 204-214.
231. Schmid, H. H. O., Schmid, P. C., Natarajan, V., N-acylated glycerophopholipids and their derivatives. Prog. Lipid. Res. 1990, 29, 1-43.
232. Darmani, N. A., Izzo, A. A., Degenhardt, B., Valenti, M. et al., Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 2005, 48, 1154-1163.
233. Matias, I., Gonthier, M. P., Petrosino, S., Docimo, L. et al., Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br. J. Pharmacol. 2007, 152, 676-690.
234. Jean-Gilles, L., Feng, S., Tench, C. R., Chapman, V. et al., Plasma endocannabinoid levels in multiple sclerosis. J. Neurol. Sci. 2009, 287, 212-215.
235. Zoerner, A. A., Stichtenoth, D. O., Engeli, S., Batkai, S. et al., Allergen challenge increases anandamide in bronchoalveolar fluid of patients with allergic asthma. Clin. Pharmacol. Ther. 2011, 90, 388-391.
236. Hermanson, D. J., Marnett, L. J., Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev. 2011, 30, 599-612.
237. Kondo, S., Kondo, H., Nakane, S., Kodaka, T. et al., 2-arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through Ca2+-dependent and -independent mechanisms. FEBS Lett. 1998, 429, 152-156.
238. Balvers, M. G. J., Verhoeckx, K. C. M., Witkamp, R. F., Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2009, 877, 1583-1590.
239. Skonberg, C., Artmann, A., Cornett, C., Hansen, S. H. et al., Pitfalls in the sample preparation and analysis of N-acylethanolamines. J. Lipid Res. 2010, 51, 3062-3073.
240. Zoerner, A. A., Batkai, S., Suchy, M. T., Gutzki, F. M. et al., Simultaneous UPLC-MS/MS quantification of the endocannabinoids 2-arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide in human plasma: minimization of matrix-effects, 2AG/1AG isomerization and degradation by toluene solvent extraction. J. Chromatogr. B 2012, 883, 161-171.
241. Estruch, R., Ros, E., Salas-Salvado, J., Covas, M. I. et al., Primary prevention of cardiovascular disease with a Mediterranean diet. N. Eng. J. Med. 2013, 368, 1279-1290.